)
Enovis (ENOV) investor relations material
Enovis Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Market and growth outlook
Orthopedics remains a stable long-term market, with patient flow a tailwind; conditions were choppy over the prior 6–9 months, with European softness followed by U.S. slowing.
Consumer sentiment, inflation, payer scrutiny, deductibles and healthcare funding were cited as factors weighing on demand.
P&R is described as a diversified, relatively de-risked 3%–4% grower; 50% of its portfolio is growing at mid-single digits or more, with recovery in France and Germany an upside.
Recon growth would benefit from greater European stability; U.S. conditions were viewed as returning toward normal, and management characterized its forecasts as conservative.
P&R portfolio and services
OA products, the NOPAIN Act and cold therapy support product growth; MotionMD and MotionIQ account acquisition has been double-digit, with 99% customer satisfaction.
Revenue cycle management and clinic workflow services are key areas for portfolio expansion, supported by established brands and customer loyalty.
Recon execution and innovation
Commercial focus over the prior 7–12 months has included customer targeting, segmentation and funnel management, alongside integration of acquired product portfolios.
U.S. hip and knee growth was nearly 6% year to date versus a 3% market estimate cited by the analyst; the pipeline includes product launches for 2027 and 2028.
The EMPOWR knee franchise remains the main driver of U.S. knee outperformance and a door-opener for competitive conversions; robotic adoption is a challenge in account targeting.
Nebula hip instruments are gaining competitive accounts; a proprietary triple-tapered collared stem is planned for late 2027 or early 2028, with better gross margin than the current offering.
Shoulder portfolio compatibility across Prima, SMR and AltiVate is intended to give clinicians multiple approaches without switching suppliers; U.S. rollout is a key opportunity.
- 5% organic growth and higher FY26 profit guidance amid persistent market headwinds.ENOV
Q3 2026 - Acquisition-driven robotics strategy and strong cash flow targets support above-market growth.ENOV
Wells Fargo 21st Annual Healthcare Conference - Acquisition of a surgical robotics leader for €176M plus milestones to boost innovation and growth.ENOV
M&A announcement - Q2 2026 saw 5% organic growth, margin gains, strong cash flow, and reaffirmed guidance.ENOV
Q2 2026 - Double-digit growth, tech innovation, and ASC expansion drive strong outlook for 2026.ENOV
2026 CG Musculoskeletal Conference - All director nominees and proposals were approved by majority, with no stakeholder questions.ENOV
AGM 2026 - Q1 2026 sales up 5%, margins and EPS improved, guidance reaffirmed amid macro headwinds.ENOV
Q1 2026 - Q1 2025 sales up 8% with margin gains; revenue outlook raised, EBITDA trimmed on tariffs.ENOV
Q1 2025 - 6%-6.5% organic growth and margin expansion expected in 2025, driven by innovation and integration.ENOV
43rd Annual J.P. Morgan Healthcare Conference 2025
)
)
)
)
)
)
)
)